Intraocular Peak Pressure in Patients Under Treatment With Fixed Combination of Bimatoprost/Timolol/Brimonidine Once Daily Versus Twice Daily
Conclusion:
Fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15%, and timolol maleate 0.5% once-a-day is more effective in reducing peak intraocular pressure as measured by the WDT than twice-a-day dosing. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - October 1, 2022 Category: Opthalmology Tags: Novel Glaucoma Insights: Original Studies Source Type: research
Bilateral Choroidal Detachment in the Absence of Previous Intraocular Surgery
The aim of this report was to present a case of bilateral choroidal detachment following treatment with topical therapy dorzolamide/timolol without history of previous surgery. An 86-year-old woman, with intraocular pressures of 40.00/36.00 mm Hg, was treated with preservative-free double therapy with dorzolamide/timolol. One week later, she presented with bilateral vision loss and irritative symptoms in the face, scalp, and ears, with well controlled pressures. The anterior exam showed LOCS III N4C3 cataracts, and the fundus and ultrasound exams revealed a bilateral infero-temporal choroidal detachment in the absence of n...
Source: Case Reports in Ophthalmology - September 30, 2022 Category: Opthalmology Source Type: research
Topical Timolol in Dermatology
Actas Dermosifiliogr. 2022 Sep 17:S0001-7310(22)00792-X. doi: 10.1016/j.ad.2021.09.014. Online ahead of print.NO ABSTRACTPMID:36126701 | DOI:10.1016/j.ad.2021.09.014 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - September 20, 2022 Category: Dermatology Authors: T Lopez-Bernal B Aranegui Source Type: research
Topical Timolol in Dermatology
Actas Dermosifiliogr. 2022 Sep 17:S0001-7310(22)00792-X. doi: 10.1016/j.ad.2021.09.014. Online ahead of print.NO ABSTRACTPMID:36126701 | DOI:10.1016/j.ad.2021.09.014 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - September 20, 2022 Category: Dermatology Authors: T Lopez-Bernal B Aranegui Source Type: research
Topical Timolol in Dermatology
Actas Dermosifiliogr. 2022 Sep 17:S0001-7310(22)00792-X. doi: 10.1016/j.ad.2021.09.014. Online ahead of print.NO ABSTRACTPMID:36126701 | DOI:10.1016/j.ad.2021.09.014 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - September 20, 2022 Category: Dermatology Authors: T Lopez-Bernal B Aranegui Source Type: research
Topical Timolol in Dermatology
Actas Dermosifiliogr. 2022 Sep 17:S0001-7310(22)00792-X. doi: 10.1016/j.ad.2021.09.014. Online ahead of print.NO ABSTRACTPMID:36126701 | DOI:10.1016/j.ad.2021.09.014 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - September 20, 2022 Category: Dermatology Authors: T Lopez-Bernal B Aranegui Source Type: research
Topical Timolol in Dermatology
Actas Dermosifiliogr. 2022 Sep 17:S0001-7310(22)00792-X. doi: 10.1016/j.ad.2021.09.014. Online ahead of print.NO ABSTRACTPMID:36126701 | DOI:10.1016/j.ad.2021.09.014 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - September 20, 2022 Category: Dermatology Authors: T Lopez-Bernal B Aranegui Source Type: research
Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan
CONCLUSION: We presented an occlusion method using available topical beta-blockers and antibiotic ointment for EGFR-TKI-induced paronychia and PG in Taiwan. The result is favorable. Further randomized control trial is urgent to validate our findings.PMID:36112905 | DOI:10.1177/10781552221122051 (Source: Cancer Control)
Source: Cancer Control - September 16, 2022 Category: Cancer & Oncology Authors: Hui-Lin Liu Cheng-Hao Chuang Chin-Ling Chen Po-Ju Wei Chih-Jen Yang Source Type: research
Urinary excretion patterns and potential risks of beta ‐blocker ophthalmic drops in sports
This study aimed at investigating the urinary excretion pattern following beta-blocker ophthalmic drops and the potential risk of constituting an adverse analytical finding (AAF) in sports. Prescribed timolol and carteolol ophthalmic drops were used in healthy participants and glaucoma patients. The urine samples were then collected to investigate the urinary excretion pattern following acute and chronic administration of the above beta-blocker ophthalmic drops. The liquid chromatograph-tandem mass spectrometry method was applied for measuring urinary beta-blockers. Our results demonstrated that the levels of both urinary ...
Source: Drug Testing and Analysis - September 13, 2022 Category: Drugs & Pharmacology Authors: Yi ‐An Lin,
Wei‐Yu Chiang,
William Chih‐Wei Chang,
Ming‐Tse Kuo,
Alexander Chen,
Mei‐Chich Hsu Tags: RESEARCH ARTICLE Source Type: research
33425 Topical timolol treatment for superficial infantile hemangiomas: Therapeutic response according to clinical subtypes
Background: Infantile hemangiomas (IHs) are the most common vascular tumors of infancy. Topical timolol, a nonselective beta-blocker, has been used for IHs as a safe and effective management option. However, few studies have evaluated the response of topical timolol according to the clinical subtypes of IHs. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - September 1, 2022 Category: Dermatology Authors: Giwook Lee, Hyun-Chang Ko, Byung-Soo Kim Source Type: research
Reversible Corneal Decompensation Caused by a Topical Dorzolamide/Timolol Fixed Combination After Descemet Stripping Automated Endothelial Keratoplasty
Conclusions:
Topical DTFC should be used with caution after corneal endothelial transplantation because of the possibility of iatrogenic corneal endothelial dysfunction. (Source: Cornea)
Source: Cornea - August 18, 2022 Category: Opthalmology Tags: Case Report Source Type: research
